March 15, 2022
Via: Drugs.comPfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age […]
March 2, 2022
Via: FierceBiotechFinch Therapeutics’ phase 3 trial for a Clostridioides difficile med has been placed on clinical hold by the FDA as the agency requests more information on how the biotech screens the donor-derived microbiome therapy for the virus that causes COVID-19. […]
Clinical Trials, Research and Development
February 21, 2022
Via: PharmaphorumAnd then came COVID-19. Twenty-three percent fewer clinical trials were launched from March through May 2020 because of the pandemic, and many clinical researchers switched to focusing on COVID-19 vaccines and treatments. COVID-19 forced research organisations to adapt. With many […]
Manufacturing, Research and Development
February 17, 2022
Via: Biopharm InternationalThermo Fisher Scientific announced that it is investing $40 million to expand its single-use technology manufacturing facility in Millersburg, Penn. The expansion is part of a $650 million multi-year investment to enhance the company’s ability to provide flexible, scalable, and […]
February 17, 2022
Via: Biopharm InternationalFDA announced on Feb. 11, 2022, that it has granted an Emergency Use Authorization (EUA) to Eli Lilly and Company for bebtelovimab, a monoclonal antibody (mAb) designed for treatment of COVID-19. The EUA covers treatment of mild to moderate COVID-19 […]
February 10, 2022
Via: PharmaphorumThe new vaccine – codenamed AZD2816 – started phase 2/3 trials as a booster dose for people vaccinated with Vaxzevria or mRNA vaccines from Pfizer/BioNTech and Moderna last June, when Beta was still the dominant SARS-CoV-2 variant of concern. In […]
February 7, 2022
Via: FiercePharmaThe FDA said it will resume domestic inspections today, lifting the pause it put into place late last year as the omicron variant of COVID-19 was sweeping across the U.S. The pause, which started Dec. 29, applied to certain inspection […]
January 26, 2022
Via: Genetic Engineering and Biotechnology NewsAt this point in the COVID-19 pandemic, two years in, people have reached varying levels of immunity to SARS-CoV-2. And, they have taken different paths to get there. Whether the path includes vaccination, a natural infection, an infection after vaccination, […]
January 24, 2022
Via: Biopharma DiveTwo years after Gilead’s drug first emerged as an option against COVID-19, Veklury is back in the spotlight. Originally developed as a medicine for hepatitis C and Ebola, Veklury became the first drug proven effective in treating COVID-19. It is […]
January 12, 2022
Via: Biopharm InternationalThe momentum of biotech and biopharma companies is on the rise in anticipation of a new wave of emerging therapies moving through the industry’s development pipeline. In addition, the COVID-19 pandemic highlighted the importance of companies that can react quickly […]
January 4, 2022
Via: FiercePharmaThe FDA further expanded the emergency use authorization for a booster shot of Pfizer-BioNTech’s Comirnaty. Johnson & Johnson’s COVID vaccine showed 85% efficacy against COVID-related hospitalization caused by omicron. The worldwide case count has risen to nearly 293 million Tuesday […]
December 29, 2021
Via: Abby HallettThe COVID-19 pandemic has demonstrated that it is essential for biopharmaceutical organizations to act quickly and become flexible in production. Experts, such as the CHEManager International team, view four factors as unsolved challenges. They claim that the first challenge is […]